Navigation Links
ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base

VANCOUVER, Canada, Oct. 14 /PRNewswire-FirstCall/ -- ProtoKinetix (OTC Bulletin Board: PKTX), a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)), announced today that it has partnered with OTC Financial Network (OTCFN), a division of National Financial Communications Corp. (NFC), to direct a comprehensive shareholder awareness campaign.

"ProtoKinetix' AAGP(TM) platform technology is ideal for a number of applications in the skin care/cosmetics, cellular therapy, blood preservation and pharmaceutical industries," said Geoffrey Eiten, president of NFC. "Last month, ProtoKinetix entered into its first licensing agreement to provide AAGP(TM) as the primary active ingredient in an anti-inflammatory cream for the sports injury market. This contract is one of several in the pipeline that position ProtoKinetix on a path to commercial success. We look forward to introducing the Company and its world-class management team to the financial community."

"We've selected to partner with OTCFN to increase our market awareness and widen our shareholder base," said Ross L. Senior, President and CEO of ProtoKinetix Inc. "We are excited to be working with a financial communications firm that has a well respected track record. We believe we can effectively enhance shareholder value by partnering with companies that offer the technical, marketing and distribution expertise to bring AAGP(TM) applications to market."

About OTC Financial Network

Since 1992, OTC Financial Network (OTCFN) has carved its niche as the nation's leading small/micro-cap investor relations and financial communications firm. OTCFN is a division of National Financial Communications Corp. ( based in Needham, MA. For information, visit

OTC Financial Network serves as special advisor to ProtoKinetix Inc. and has received fees for services, including two hundred and fifty-thousand shares of restricted stock, in addition to an option to purchase two-hundred fifty-thousand shares at an exercise price of twenty cents per share, for the creation and implementation of an awareness program. This is not an offer to buy or sell securities. Information or opinions in this release are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. A full disclaimer can be found online by visiting

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP(TM)) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialog with major corporations and institutions who have contacted the Company about the broad range of applications for AAGP(TM) products. For more information, visit

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.


Ross L. Senior, LLB - President and CEO

Company Office: Investor Contact:

Suite # 1500 ProtoKinetix Inc.

885 West Georgia Street 604-687-9887

Vancouver, BC V6C 3E8

At OTC Financial Network:

Rick McCaffrey


SOURCE ProtoKinetix
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65
2. Vista Partners Updates Coverage; Maintains $3.20 Target Price
3. Mentice, Inc. and Education Management Solutions, Inc. Form OEM Partnership
4. Creators of Britains Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008
5. Mirixa Corporation and the APhA Foundation Form Partnership
6. New Partnership Integrates Vibration Therapy Into Stem Cell Procedures
7. Samaritan Partners Forgetful Rat Model to Taconic to Commercialize
8. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
9. Riverside Partners Sells MicroCal to GE Healthcare
10. onTargetjobs and ClearedConnections Announce Online Recruitment Partnership
11. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
Post Your Comments:
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh ... Insertion points for in-line sensors can represent a weak spot where leaking process ... series of retractable sensor housings , which are designed to tolerate extreme process ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Technologies, Inc., on being named to Deloitte's 2015 Technology Fast 500 list of ... OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up orthodontic ...
(Date:11/24/2015)... 2015 Capricor Therapeutics, Inc. (NASDAQ: ... discovery, development and commercialization of first-in-class therapeutics, today announced ... is scheduled to present at the 2015 Piper Jaffray ... EST, at The Lotte New York Palace Hotel in ... . --> . ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
(Date:10/27/2015)... 2015 Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ... , so that they can be quantitatively analyzed with ... Munich, Germany , October 28-29, 2015. SMI,s Automated ... mobile eye tracking videos created with SMI,s Eye ...
Breaking Biology News(10 mins):